Proficio Capital Partners LLC Buys Shares of 2,086 Stryker Corporation $SYK

Proficio Capital Partners LLC acquired a new position in Stryker Corporation (NYSE:SYK) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,086 shares of the medical technology company’s stock, valued at approximately $657,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. VanderPol Investments L.L.C. grew its position in shares of Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after purchasing an additional 28 shares during the last quarter. KCM Investment Advisors LLC raised its stake in shares of Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after purchasing an additional 28 shares in the last quarter. Rossby Financial LCC lifted its holdings in shares of Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after acquiring an additional 28 shares during the period. Tcfg Wealth Management LLC lifted its stake in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares during the period. Finally, ICW Investment Advisors LLC boosted its stake in Stryker by 0.6% in the 4th quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock valued at $1,791,000 after buying an additional 30 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Argus set a $370.00 price target on Stryker in a research report on Thursday, July 9th. Citizens Jmp decreased their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a report on Monday, August 3rd. Finally, Evercore set a $350.00 target price on Stryker in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Price Performance

Shares of NYSE SYK opened at $312.10 on Thursday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The stock has a market capitalization of $119.71 billion, a price-to-earnings ratio of 32.34, a PEG ratio of 1.99 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The business has a 50-day moving average of $329.60 and a 200-day moving average of $330.33.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Director Mary Brainerd purchased additional Stryker shares on September 2, increasing her personal stake. Insider buying can signal confidence in the company’s valuation and outlook, although the purchase alone is unlikely to materially change earnings expectations. Stryker Insider Makes Bold New Move With Fresh Share Purchase
• Positive Sentiment: Stryker received FDA De Novo authorization for SportSuite Vision, its surgical application for Apple Vision Pro, and completed the first reported hip arthroscopy using the system. The technology could strengthen Stryker’s digital-surgery and orthopedic innovation offerings, though commercial adoption remains to be demonstrated. Stryker introduces FDA-authorized surgical application for Apple Vision Pro
• Positive Sentiment: Stryker agreed to acquire ZuriMED, adding the FiberLocker System and expanding its shoulder-care and rotator-cuff portfolio. The deal could broaden Stryker’s orthopedic product lineup and growth opportunities. Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
• Neutral Sentiment: Analysts remain broadly optimistic about Stryker’s longer-term prospects even as the shares have underperformed the broader market. The company’s latest reported quarter exceeded earnings expectations, but its valuation remains relatively elevated, which can increase sensitivity to growth concerns. Is Stryker Stock Underperforming the Nasdaq?
• Negative Sentiment: The recent underperformance suggests investors may be focused more on valuation, execution, and market-wide factors than on the new product announcements. The ZuriMED transaction also introduces integration and spending risks, with financial terms and its near-term earnings contribution not specified in the available reports.

Insider Buying and Selling at Stryker

In other Stryker news, insider Debra King sold 826 shares of Stryker stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Dylan Bram Crotty sold 441 shares of Stryker stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 351,267 shares of company stock valued at $118,197,701 in the last quarter. 4.60% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.